Regulation of glucose metabolism by incretins: implications for treatment of type 2 diabetes

被引：0
作者：
Saito, Rie [1 ]
Harada, Norio [1 ]
机构：
[1] Univ Fukui, Sch Med Sci, Dept Endocrinol & Metab, 23-3 Matsuoka Shimoaizuki,Eiheiji Cho, Fukui 9101193, Japan
来源：
DIABETOLOGY INTERNATIONAL | 2024年
关键词：
Incretin; GIP; GLP-1; Incretin effect; Insulin secretion; GLUCAGON-LIKE PEPTIDE-1; DEPENDENT INSULINOTROPIC POLYPEPTIDE; NON-ASIANS; SECRETION; TOLERANCE; MELLITUS; EFFICACY; GLP-1; GIP;
D O I：
10.1007/s13340-024-00781-y
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Gastrointestinal hormones that potentiate insulin secretion from pancreatic beta-cells are called incretins. Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are the major incretins. Incretin-mediated stimulation of insulin secretion (incretin effect) plays an important role in lowering postprandial blood-glucose levels. Incretin effect is reduced under diabetic condition. Several mechanisms have been reported for the reduction of incretin effect. Incretin-related drugs are used worldwide for the treatment of type 2 diabetes. In addition, several new incretin-related drugs have been developed and are expected to be available in clinical practice.
引用
收藏
页数：5
相关论文
共 31 条
  • [1] A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes-2nd Edition (English version)
    Bouchi, Ryotaro
    Kondo, Tatsuya
    Ohta, Yasuharu
    Goto, Atsushi
    Tanaka, Daisuke
    Satoh, Hiroaki
    Yabe, Daisuke
    Nishimura, Rimei
    Harada, Norio
    Kamiya, Hideki
    Suzuki, Ryo
    Yamauchi, Toshimasa
    [J]. DIABETOLOGY INTERNATIONAL, 2024, 15 (03) : 327 - 345
  • [2] Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies
    Calanna, S.
    Christensen, M.
    Holst, J. J.
    Laferrere, B.
    Gluud, L. L.
    Vilsboll, T.
    Knop, F. K.
    [J]. DIABETOLOGIA, 2013, 56 (05) : 965 - 972
  • [3] Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes Systematic review and meta-analysis of clinical studies
    Calanna, Salvatore
    Christensen, Mikkel
    Holst, Jens J.
    Laferrere, Blandine
    Gluud, Lise L.
    Vilsboll, Tina
    Knop, Filip K.
    [J]. DIABETES CARE, 2013, 36 (10) : 3346 - 3352
  • [4] LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
    Coskun, Tamer
    Sloop, Kyle W.
    Loghin, Corina
    Alsina-Fernandez, Jorge
    Urva, Shweta
    Bokvist, Krister B.
    Cui, Xuewei
    Briere, Daniel A.
    Cabrera, Over
    Roell, William C.
    Kuchibhotla, Uma
    Moyers, Julie S.
    Benson, Charles T.
    Gimeno, Ruth E.
    D'Alessio, David A.
    Haupt, Axel
    [J]. MOLECULAR METABOLISM, 2018, 18 : 3 - 14
  • [5] Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    Davies, Melanie J.
    Aroda, Vanita R.
    Collins, Billy S.
    Gabbay, Robert A.
    Green, Jennifer
    Maruthur, Nisa M.
    Rosas, Sylvia E.
    Del Prato, Stefano
    Mathieu, Chantal
    Mingrone, Geltrude
    Rossing, Peter
    Tankova, Tsvetalina
    Tsapas, Apostolos
    Buse, John B.
    [J]. DIABETOLOGIA, 2022, 65 (12) : 1925 - 1966
  • [6] Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study
    DeFronzo, Ralph A.
    Okerson, Ted
    Viswanathan, Prabhakar
    Guan, Xuesong
    Holcombe, John H.
    MacConell, Leigh
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (10) : 2943 - 2952
  • [7] Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
    Drucker, Daniel J.
    Sherman, Steven I.
    Gorelick, Fred S.
    Bergenstal, Richard M.
    Sherwin, Robert S.
    Buse, John B.
    [J]. DIABETES CARE, 2010, 33 (02) : 428 - 433
  • [8] The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets
    El, Kimberley
    Douros, Jonathan D.
    Willard, Francis S.
    Novikoff, Aaron
    Sargsyan, Ashot
    Perez-Tilve, Diego
    Wainscott, David B.
    Yang, Bin
    Chen, Alex
    Wothe, Donald
    Coupland, Callum
    Tschoep, Mattias H.
    Finan, Brian
    D'Alessio, David A.
    Sloop, Kyle W.
    Mueller, Timo D.
    Campbell, Jonathan E.
    [J]. NATURE METABOLISM, 2023, 5 (06) : 945 - +
  • [9] Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes
    Fukushima, M
    Suzuki, H
    Seino, Y
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2004, 66 : S37 - S43
  • [10] The integrated incretin effect is reduced by both glucose intolerance and obesity in Japanese subjects
    Hamasaki, Akihiro
    Harada, Norio
    Muraoka, Atsushi
    Yamane, Shunsuke
    Joo, Erina
    Suzuki, Kazuyo
    Inagaki, Nobuya
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2024, 15
1234